معالجة اعتلال المطخة الشيخي النتحي بحقن البيفاسيزوماب داخل الزجاجي

الموضوعات

طب

روابط وملفات

التعريف والنوع

رقم الوثيقة

ed6fa90a-1034-400e-b188-9dd9986be929

رقم العقد

0

نوع الوسائط

Crawler

نوع المحتوى

الرسائل العلمية

صيغة المصدر

رسائل ماجيستير

نوع الملف

pdf text

أسماء الملفات

1967124_1.pdf

بيانات النشر

ترجمة العنوان

Treatment of Exudative Age-related Macular Degeneration by Intravitreal Injection of Bevacizumab

ألقاب المؤلفين

[{"name_ar":" شفان عمر رشك","title_ar":"اعداد","title_en":"Preparation"},{"name_ar":"عمار كيالي","title_ar":"اشراف","title_en":"Supervision"}]

اللغة

Arabic

المصدر والدورية

اسم المصدر

معالجة اعتلال المطخة الشيخي النتحي بحقن البيفاسيزوماب داخل الزجاجي

المحتوى والصفحات

عدد الصفحات

0

ترجمة الملخص

Introduction: In developing countries,age-related macular degeneration is considered as first cause of blindness in individuals over 65 years old. AMD is associated with gradual impairment of central vision due to a degenerat in process in the retina .many patients with AMD develop rapid impairment of vision due to CNV formation which lead to accumulation of fluid intraretina ,subretina (SRF),and/or sub RPE (PED).the most recent researches studied the conflict effect of antivascular endothelial growth factor in resolution of CNV and its complications,I.e.Bevacizumb Aim of research: assessment the efficacy and safety of intravitreal injection of BEVACIZUMAB in treatment of exudative age-related macular degeneration. Methods: eighteen(18)patients participated in the study .all patients were treated with (3) intravitreal injection of Bevacizumab, with 4 weeks interval .follow up was 4 weeks after each injection and then after 6 month from the first one. The patients underwent Snellen visual acuity testing, ophthalmoscopic examination, optical coherence tomography (OCT),fluresine angiography (FA) and intraocular pressure measurement at baseline and follow-up visits. the patients were divided into two groups, depending on OCT findings, the first one (10 patients)represents patients with intra and/or subretinal fluid(SRF) without sub RPE fluid(PED),the second one (8 patients) represents those with sub RPE fluid (PED) with/or without intra or subretinal fluid(SRF).Results: The first group included (10) eyes of (10) patients , (7) males (70%) and (3) females (30%). Follow up had a mean of (24) weeks. Visual acuity has maximum improvement (1,3points) after6 monthes , Mean CMT at baseline was 353,8micron decreased to 211,2micron after6monthes,no changes in IOP was noticed. The second group included (8) eyes of (8) patients, (6) males (75%) and (2) females (25%).Follow up had a mean of (24) weeks. Visual 67acuity has maximum improvement (0.75 points) after 3 monthes and decreased to (0.625) point after 6 monthes, Mean CMT at baseline was 365micron decreased to 232,4micron after6monthes.no change in IOP was noticed. mean thickness of sub RPE fluid at baseline was 181 microns ,decreased slightly to 165,4microns.Conclusion: Intravitreal injections of bevacizumab may be an effective treatment of neovascular AMD in short-term follow up .with decreased CRT, decreased subretinal fluid ,and improvement of vision, it seems that bevacizumab injections don't have good effect on sub RPE fluid.so patients with isolated PED may don't benefit from bevacizumab injections.

إشراف وإعداد

الإشراف

عمار كيالي

الإعداد

شفان عمر رشك

الاقتباسات الببليوغرافية